These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20615877)

  • 1. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.
    Riemer AB; Keskin DB; Zhang G; Handley M; Anderson KS; Brusic V; Reinhold B; Reinherz EL
    J Biol Chem; 2010 Sep; 285(38):29608-22. PubMed ID: 20615877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
    Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach.
    Yao Y; Huang W; Yang X; Sun W; Liu X; Cun W; Ma Y
    Vaccine; 2013 Apr; 31(18):2289-94. PubMed ID: 23499609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
    Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
    Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
    Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
    Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
    Street MD; Doan T; Herd KA; Tindle RW
    Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
    Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
    Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
    Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
    J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones.
    Schreurs MW; Scholten KB; Kueter EW; Ruizendaal JJ; Meijer CJ; Hooijberg E
    J Immunol; 2003 Sep; 171(6):2912-21. PubMed ID: 12960314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
    Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.
    Bourgault Villada I; Moyal Barracco M; Berville S; Bafounta ML; Longvert C; Prémel V; Villefroy P; Jullian E; Clerici T; Paniel B; Maillère B; Choppin J; Guillet JG
    Clin Exp Immunol; 2010 Jan; 159(1):45-56. PubMed ID: 19843089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
    Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
    J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
    Bauer M; Wagner H; Lipford GB
    Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone.
    Kim KH; Dishongh R; Santin AD; Cannon MJ; Bellone S; Nakagawa M
    Cancer Immun; 2006 Jun; 6():9. PubMed ID: 16808432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.